Compare KB Financial Group, Inc. (KB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Summit Therapeutics Inc — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $41.21B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: KB Financial Group, Inc. is far larger — about 3.4× Summit Therapeutics Inc's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KB | SMMT | |
|---|---|---|
Market Cap | $41.21B | $12.06B |
Sector | Financials | Health |
52-Week High | $124.01 | $26.98 |
52-Week Low | $77.50 | $12.55 |
Dividend Yield | 2.67% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial trades at $117.85, down 2.39% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.36, P/B of 0.98, and net income margin of 27.82%. Recent earnings beats in Q1 and Q2 2026 highlight operational strength, while cash flow trends show variability with a net inflow of $4.41T in 2025.
The outlook is positive given earnings momentum and undervaluation relative to peers, but risks include volatile cash flows and dependence on interest rates. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism for upside potential amid economic uncertainties.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
